ABCB4 p.Tyr403His
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 17726488
[PubMed]
Degiorgio D et al: "Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3)."
No.
Sentence
Comment
18
The two TMDs contain specific sites for substrate binding and translocation, whereas the two NBDs, which display a high degree of sequence similarity with the equivalent domain of ABC transporters, couple the energy obtained from ATP hydrolysis to substrate transport.8 The ICDs are deemed to be involved in mediating the coupling between NBD conformational changes and the reorientation of TM helices concomitant with substrate extrusion.9 The ABCB1 gene, one of the most extensively studied ABC transporters, is responsible for the human multidrug resistance phenotype that is a rapidly growing obstacle to the treatment of numerous infectious diseases, including human immunodeficiency10 and malaria.11 The properties of this transporter are also exploited in cancer pharmacological therapy where ABCB1 translocates the chemotherapeutic drugs and other molecules with a broad but defined specificity.12 A gene duplication of ABCB1 and additional mutations selected as advantageous have created in mammals the T715I G723E L724AfsX744 A737V G954S G762X T775M G126E S320F A840D OUT IN Linker region F357L L701P A364V NBD-NH2 terminal NBD-COOH terminal A1193T NH2 COOH 1 2 54 6 7 8 129 11 10 EC2EC1 ICD2 A250P Y279X A286V ICD1 R159X T175A ICD3 EC3 EC4 EC6EC5 ICD4 ICD6 ICD5 E888X Y403H V475A A511T E558K R590Q T593A M630V 3 S379KfsX413 P726T Figure 1 (a) Localization of the 29 mutations identified in this study in the ABCB4 protein, schematically represented in its domains.
X
ABCB4 p.Tyr403His 17726488:18:1279
status: NEW76 Two patients were homozygous, one for the mutation p.G954S and the second for p.Y403H (Table 3).
X
ABCB4 p.Tyr403His 17726488:76:80
status: NEW84 There are no PFIC3 epidemiologic data available to date; however, knowing that the number of newborns in Italy has been on average 500 000/year in the last 14 years (http://demo.istat.it/), since we observed 18 patients with ABCB4-mutated alleles born within a 14-year period (with Table 2 Mutations identified in ABCB4 Type of mutationb Exons cDNA locusa Missense Frameshift or nonsense ABCB4-predicted domain GenBank accession numberc Exon 6 c.377G4A G126E TM2 DQ861346 Exon 6 c.523A4G T175A ICD1 Exon 6 c.475C4T R159X ICD1 DQ861347 Exon 8 c.748G4C A250P ICD2 DQ861349 Exon 9 c.837T4A Y279X ICD2 DQ861348 Exon 9 c.857C4T A286V ICD2 DQ861350 Exon 9 c.959C4T S320F TM5 Exon 10 c.1069T4C F357L ICD3 DQ861351 Exon 10 c.1091C4T A364V ICD3 DQ861352 Exon 11 c.1135_1136insAA S379KfsX413 ICD3 DQ861353 Exon 11 c.1207T4C Y403H NBD-NH2 A-loop EF035007 Exon 13 c.1424T4C V475A NBD-NH2 ter DQ861354 Exon 13 c.1531G4A A511T NBD-NH2 ter DQ861355 Exon 14 c.1672G4A E558K NBD-NH2 ter DQ861356 Exon 15 c.1769G4A R590Q NBD-NH2 ter Exon 15 c.1777A4G T593A NBD-NH2 ter DQ861357 Exon 15 c.1888A4G M630V NBD-NH2 ter DQ861358 Exon 17 c.2102T4C L701P Linker region DQ861359 Exon 17 c.2144C4T T715I TM7 DQ861360 Exon 17 c.2168G4A G723E TM7 DQ861361 Exon 17 c.2169_2170insG L724AfsX744 TM7 DQ861362 Exon 17 c.2176C4A P726T TM7 DQ861363 Exon 17 c.2210C4T A737V EC4 DQ861364 Exon 18 c.2284G4T G762X TM8 DQ861365 Exon 19 c.2324C4T T775M TM8 Exon 21 c.2519C4A A840D TM9 DQ861366 Exon 21 c.2662G4T E888X ICD5 DQ861367 Exon 23 c.2860G4A G954S TM11 DQ861368 Exon 27 c.3577G4A A1193T NBD-COOH ter DQ861369 a cDNA sequence is based on reference sequence GenBank NM_018849.
X
ABCB4 p.Tyr403His 17726488:84:814
status: NEW102 Table 3) includes seven cases: p.Y403H, p.V475A, p.A511T, p.E558K, p.R590Q, p.T593A and p.A1193T.
X
ABCB4 p.Tyr403His 17726488:102:33
status: NEW107 In particular, the two missense mutations p.Y403H and p.E558K are located in protein sites already extensively investigated in other ABC transporters.
X
ABCB4 p.Tyr403His 17726488:107:44
status: NEW116 13_FRRLWPTIAPFKAGLIVAGVALILNAASDTFMLSLLKPLLDDG_55.. 13_FRRLWPTIAPFKAGLIVAGIALILNAASDTFMLSLLKPLLDDG_55.. 13_FKRLWTYIRLYKAGLVVSTIALVINAAADTYMISLLKPLLDEG_55.. 2_IKRYLQFVKPYKYRIFATIIVGIIKFGIPMLIPLLIKYAIDGV_44.. ...836_AQNIANLGT_844... ..1148_AQNIANLGT_1156.. ...833_AQNTANLGT_841... ...835_AQNTANLGT_843... ...987_AQNTANLGT_995... ...748_AQNTANLGT_756... ...837_TQNIANLGT_845... ...147_VREGASIIG_155... ...147_VREGASIIG_155... ...147_VREGASIIG_155... ..143_WLDCITIII_151... Hs_ABCB4 Pt_ABCB4 Mm_ABCB4 Rn_ABCB4 Bt_ABCB4 Md_ABCB4 Hs_ABCB1 Esch-coli_Msba Salm-typh_Msba Vibrio-ch_Msba Staph-au_Sav1866 950_FSYAGCFRF_958.... 1262_FSYAGCFRF_1270.... 947_FSYAGCFRF_955.... 949_FSYAGCFRF_957.... 1101_FSYAGCFRF_1109 862_FSYAGCFRF_870.... 951_FSYAGCFRF_959.... 261_LALAFVLYA_269.... 261_LALAFVLYA_269.... 261_LALFAVLFL_269.... 257_IGPIIVIGV_265.... 1189_RIAIARALI_1197.... 1494_RIAIARALI_1502.... 1179_RIAIARALI_1187.... 1181_RIAIARALI_1189.... --------- 1093_RIAIARALI_1101.... 1183_RIAIARALV_1191.... .488_RIAIARALL_496.... .488_RIAIARALL_496.... .488_RVAIARALL_496.... .485_RLSIARIFL_493.... Y403H T593AR590Q M630V L701P T715I P726TG723E A737V G954S A1193TA840D Figure 2 Multiple sequence alignment of ABCB4 protein sequences.
X
ABCB4 p.Tyr403His 17726488:116:1083
status: NEW
PMID: 21119540
[PubMed]
Colombo C et al: "Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations."
No.
Sentence
Comment
107
Nucleotidechange (effectonprotein) Predictionscoresby PolyPhenanalysis Nucleotidechange (effectonprotein) Predictionscoresby PolyPhenanalysis Referencefor eachgenotype 1[1-I]c.475C>T(p.R159X)XUnknownUnknown20 1[1-II]c.475C>T(p.R159X)XUnknownUnknownThisstudy 2[2-I]c.523A>G(p.T175A)0.774c.1069T>C(p.F357L)þc.2324C>T(p.T775M)1.079þ0.59720 3[3-I]c.1135_1136insAA(p.S379KfsX413)Xc.2102T>C(p.L701P)2.22620 4[4-I]c.2662G>T(p.E888X)Xc.748G>C(p.A250P)Rc.1888A>G(p.M630V)1.871R1.67720 5[5-I]c.959C>T(p.S320F)1.287c.857C>T(p.A286V)1.40820 6[6-I]c.377G>A(p.G126E)1.998c.1531G>A(p.A511T)2.1720 6[6-II]c.377G>A(p.G126E)1.998c.1531G>A(p.A511T)2.1720 7[7-I]c.2176C>A(p.P726T)2.086c.1769G>A(p.R590Q)þc.2284G>T(p.G762X)2.623RX20 8[8-1]c.1091C>T(p.A364V)1.343c.2210C>T(p.A737V)0.21720 9[9-I]c.1777A>G(p.T593A)2.044UnknownUnknown20 10[10-I]c.2144C>T(p.T715I)0.383UnknownUnknown20 11[11-I]c.2519C>A(p.A840D)1.803c.1424T>C(p.V475A)2.60320 12[12-I]c.1672G>A(p.E558K)2.486c.2168G>A(p.G723E)Rc.3577G>A(p.A1193T)1.548þ2.34120 12[12-II]c.1672G>A(p.E558K)2.486c.2168G>A(p.G723E)Rc.3577G>A(p.A1193T)1.548þ2.34120 13[13-I]c.2860G>A(p.G954S)0.245c.2860G>A(p.G954S)0.24520 14[14-I]c.523A>G(p.T175A)0.774UnknownUnknown20 15[15-I]c.959C>T(p.S320F)1.287c.837T>A(p.Y279X)X20 16[16-I]c.523A>G(p.T175A)0.774UnknownUnknown20 17[17-I]c.2169_2170insG(p.L724AfsX744)Xc.2169_2170insG(p.L724AfsX744)X20 17[17-II]c.2169_2170insG(p.L724AfsX744)Xc.2169_2170insG(p.L724AfsX744)X20 18[18-I]c.1207T>C(p.Y403H)2.798c.1207T>C(p.Y403H)2.79820 19[19-I]c.208G>C(p.G70R)þc.1769G>A(p.R590Q)1.497þ2.623c.959C>T(p.S320F)1.287Thisstudy 19[19-II]c.208G>C(p.G70R)þc.1769G>A(p.R590Q)1.497þ2.623c.959C>T(p.S320F)1.287Thisstudy 19[19-III]c.208G>C(p.G70R)þc.1769G>A(p.R590Q)1.497þ2.623c.959C>T(p.S320F)1.287Thisstudy 20[20-I]c.217C>G(p.L73V)0.489UnknownUnknown22,thisstudy 21[21-I]c.959C>T(p.S320F)1.287c.959C>T(p.S320F)1.28716,thisstudy 22[22-I]c.1207T>C(p.Y403H)2.798UnknownUnknownThisstudy Xidentifiesmutationsthatpredictprematureterminationoftranslation.PolyPhenpredictionwithPSICscoredifferencesbelow1.5definebenignsubstitutions;PSICscoredifferencesencompassing between1.5and2.0(bold)definesubstitutionspossiblydamaging,whereasabove2.0(underlined)definesubstitutionsprobablydamaging.
X
ABCB4 p.Tyr403His 21119540:107:1479
status: NEWX
ABCB4 p.Tyr403His 21119540:107:1502
status: NEWX
ABCB4 p.Tyr403His 21119540:107:1948
status: NEW128 This may be the case for patient 18-I, who had moderate ABCB4 immunostaining (60% of the cells, Fig. 2) and was homozygous for the missense mutation p.Y403H.
X
ABCB4 p.Tyr403His 21119540:128:151
status: NEW
PMID: 24045840
[PubMed]
Degiorgio D et al: "Two ABCB4 point mutations of strategic NBD-motifs do not prevent protein targeting to the plasma membrane but promote MDR3 dysfunction."
No.
Sentence
Comment
3
According to our model of tertiary structure, this mutation affects the Q-loop, whereas the p.(Y403H) mutation, that we already described in two other families, involves the A-loop.
X
ABCB4 p.Tyr403His 24045840:3:95
status: NEW7 On the contrary, cholesterol (Chol) release, after 1 and 3 mM sodium taurocholate stimulation, was higher in the mutant-transfected cell lines than that in the wild-type and was particularly enhanced in cells transfected with the p.Y403H-construct.In summary, our data show that both mutations do not seem to affect protein expression, but are able to reduce the efflux of phosphatidylcholine associated with increase of Chol, thereby promoting the formation of toxic bile.
X
ABCB4 p.Tyr403His 24045840:7:232
status: NEW31 The nucleotide change c.1207T4C that encodes the mutant protein characterized by p.(Y403H) was previously described at homozygous state in the child of family B and at heterozygous state in the other members of family B and C.14 To evaluate the expression of MDR3 in vitro, we used two plasmids: one containing the full-length cDNA of ABCB4 wild type on a pcDNA3.1/ Hygro( &#fe; ) backbone (pcDNA3.1/Hygro( &#fe; )/ABCB4) and the second containing the b-galactosidase gene (pcDNA3.1.V5/His-lacZ).
X
ABCB4 p.Tyr403His 24045840:31:84
status: NEW33 The plasmid pcDNA3.1/Hygro(&#fe; )/ABCB4 was also used to obtain clones harboring the p.(Y403H) or the p.(L481R) mutation.
X
ABCB4 p.Tyr403His 24045840:33:89
status: NEW80 Wild-type cells secreted more PC and Chol than the mutant ones; PC: 3.417 nmol/mg proteins versus 1.410 for p.L481R and 2.346 for p.Y403H and Chol: 4.476 nmol/mg proteins versus 3.193 for p.L481R and 3.811 for p.Y403H (Figures 4a and b; Supplementary Table 1).
X
ABCB4 p.Tyr403His 24045840:80:132
status: NEWX
ABCB4 p.Tyr403His 24045840:80:212
status: NEW82 Although wild-type cells and p.Y403H mutant showed similar fold increases in PC excretion, p.L481R mutant showed higher sensitivity to NaTC reaching 11-fold increase in PC secretion at 3 mM compared with the absence of NaTC (Supplementary Table 1).
X
ABCB4 p.Tyr403His 24045840:82:31
status: NEW85 In particular, p.Y403H displayed higher Chol excretion compared with wild-type cells at 3.0 mM NaTC: 9.04 versus 6.05 by referring at parameter 'fold increase` and 34.438 versus 27.074 (nmol/mg proteins) by referring at parameter 'absolute amount`.
X
ABCB4 p.Tyr403His 24045840:85:17
status: NEW92 Lanes 5 and 6 show the stable expression of p.L481R-ABCB4 and p.Y403H, respectively.
X
ABCB4 p.Tyr403His 24045840:92:64
status: NEW94 The PC/Chol ratio showed a similar trend in absence or with 1.0 and 3.0 mM of NaTC; it was reduced in both mutants, particularly in Y403H cells, whereas an inverted trend was shown after treatment with 0.5 mM NaTC.
X
ABCB4 p.Tyr403His 24045840:94:132
status: NEW96 As reported in Figure 4c, in mutant Y403H cells low values of PC efflux are associated with high Chol into the culture medium.
X
ABCB4 p.Tyr403His 24045840:96:36
status: NEW98 In this study, besides reporting the identification of a novel ABCB4 mutation (p.(L481R)) within the Q-loop in three siblings suffering from juvenile cholelithiasis, we demonstrate that this mutation, stably transfected in HUH28 cells, as well as the mutation p.(Y403H), previously described by our group,14 do not prevent protein targeting to the plasma membrane but induce an abnormal efflux of PC and Chol.
X
ABCB4 p.Tyr403His 24045840:98:263
status: NEW102 The p.(L481R) mutation was identified in three out of seven affected siblings belonging to family A, whereas the already characterized p.(Y403H) mutation6,14 was identified in four affected members belonging to other two families.
X
ABCB4 p.Tyr403His 24045840:102:138
status: NEW104 In particular, the infant bearing the homozygous p.(Y403H) mutation was diagnosed as PFIC-3 at the age of 3 months, and at the age of 3 years presented compensated cirrhosis with portal hypertension; (ii) a single mutant allele can be associated with hepatobiliary diseases with less significant and highly variable clinical features.
X
ABCB4 p.Tyr403His 24045840:104:52
status: NEW111 Analysis of PC (a) and Chol (b) secretion, and PC-Chol correlation (c) in MDR3 wild-type, MDR3 p.Y403H and MDR3 p.L481R cells.
X
ABCB4 p.Tyr403His 24045840:111:97
status: NEW118 As for biliary Chol, it is widely documented that in mice it is excreted into the canalicular lumen through different pathways; among them, a relevant rate of efflux is because of the direct activity of the specific ABC hemitransporters G5 and G8 (ABCG5 and ABCG8).27 Our data show that, in absence or low concentration of NaTC, mutant cells have less Chol efflux ability than wild-type cells, and this direct proportionality between reduced excretion of biliary PC and Chol was originally described in Mdr2/ mice.7 Instead, higher concentrations of NaTC seem to increase Chol efflux by mutant cells, with a maximum value obtained in presence of the p.Y403H mutation so that the ratio between PC and Chol is inverted.
X
ABCB4 p.Tyr403His 24045840:118:655
status: NEW
No.
Sentence
Comment
106
By contrast, the Y403H and L481R mutations did not alter membrane targeting but decreased ABCB4 activity [61].
X
ABCB4 p.Tyr403His 24953525:106:17
status: NEW